Announcing a new article publication for BIO Integration journal. Antibody-drug conjugates (ADCs) have the following advantages: target specificity; wide therapeutic index; and prolonged circulation half-life. A key limitation of ADCs, however, is the large size (∼150 kDa), which markedly slows diffusion through the interstitium of solid tumors and prevents efficient penetration. To address the size issue of ADCs in targeted drug delivery, the authors of this article developed a HER2-targeting peptide-mertansine conjugate (HER2-TPMC) and conducted a head-to-head comparison with HER2-targeting antibody-mertansine conjugate (HER2-TAMC) as a possible alternative for high-penetration breast cancer therapeutics. As expected, a pharmacokinetic (PK) assay revealed that HER2-TP had lower levels persisting in the circulation after 1 h (∼75%) compared to 85% of HER2-targeting antibody (HER2-TA). The cellular cytotoxic effect of HER2-TPMC was similar to HER2-TAMC in the HER2+ BT474 breast cancer cell line, thus demonstrating similar bioactivity of both conjugates. HER2-TPMC not only revealed higher uptake and specificity in in vitro 3D spheroid cultures compared to the parental drug, mertansine, but HER2-TPMC also had a significant retention in the spheroids. This finding was in stark contrast to HER2-TAMC, a large-sized conjugate which was not able to penetrate the spheroid barrier, thus resulting minimal penetration. In vivo tumoral uptake in a BT474 orthotopic model indicated increased tumor uptake and penetration of HER2-TP compared to parental drug and HER2-TAMC.
The authors successfully developed a HER2-targeting peptide-mertansine conjugate with specific cellular uptake that resulted in longer retention times in vitro and in vivo. HER2-TPMC (∼5 kDa in size) exhibited rapid tissue penetration and enhanced tumoral uptake and retention in vitro and in vivo. Therefore, HER2-TPMC is a reasonable alternative for HER2-positive cancer chemotherapeutics.

BIO Integration is fully open access journal which will allow for the rapid dissemination of multidisciplinary views driving the progress of modern medicine.

As part of its mandate to help bring interesting work and knowledge from around the world to a wider audience, BIOI will actively support authors through open access publishing and through waiving author fees in its first years. Also, publication support for authors whose first language is not English will be offered in areas such as manuscript development, English language editing and artwork assistance.


Full bibliographic information
Published on 15/05/2023 by Compuscript Ltd
Title: HER-targeting Peptide Drug Conjugate with Better Penetrability for Effective Breast Cancer Therapy,
Authors: Liang, Yixia; Lei, Rong; Tan, Jiabao; Fang, Junyue; Yu, Lin; Tan, Shiyu; Nie, Yan; Jiang, Qiongchao; Xiao, Xiaoyun; Er Saw, Phei, BIO Integration, 2023,

BIOI is now open for submissions; articles can be submitted online at:

Please visit to learn more about the journal.
Editorial Board:

Please visit to learn more about the journal.
Editorial Board:

BIOI is available on the IngentaConnect platform ( and at the BIO Integration website (

Submissions may be made using ScholarOne (

There are no author submission or article processing fees.

Follow BIOI on Twitter @JournalBio; Facebook ( and LinkedIn (

ISSN 2712-0074
eISSN 2712-0082